X

Trial Profile

An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ublituximab (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Sponsors TG Therapeutics

Most Recent Events

07 Mar 2025 According to a TG Therapeutics Inc media release, data from this study presented at the American Academy of Neurology 2025 annual meeting, being held April 5 - 9, 2025, in San Diego, California.
24 Jan 2025 Planned End Date changed from 1 Apr 2027 to 1 Feb 2030.
24 Jan 2025 Planned primary completion date changed from 1 Apr 2027 to 1 Feb 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com